In an official dispatch, the health ministry reminded that on the 29th of December, 2021, the Federal Commission for the Protection Against Sanitary Risks ( FCPASR) ruled as appropriate the authorization for emergency use of the Cuban immunogen.
This ruling was approved under the distinctive denomination of recombination protein of the SARS-CoV-2 virus receptor binding domain, developed by the Center for Genetic Engineering and Biotechnology of the Ministry of Public Health of Cuba.
The National Vaccination Campaign against Influenza and COVID-19 for the winter season, 2023-2024 is ongoing in Mexico from the 16th of October 2023 until the 31st of March 2024. During this period 54 million 600 thousand doses will be applied.
jrr/rgh/lma
